Part 2 maintenance-treatment definition

Editorial approval scope: The team checked current source fidelity, scope boundaries, dates, arithmetic, reader usefulness, practical workflow, and general-information limitations.

Current rule checkpoint

Live 42 CFR 2.11 defines maintenance treatment as long-term pharmacotherapy for individuals with substance use disorders that reduces pathological pursuit of reward or relief and supports remission of SUD-related symptoms. The definition classifies a service or program function. It does not select medication, dosage, duration, setting, or care for an individual.

Use each component of the definition

Current 42 CFR 2.11 identifies long-term pharmacotherapy, the SUD population, reduced pathological pursuit of reward or relief, and support for symptom remission. Record the program, service, medication role, purpose, clinical source, duration model, setting, and Part 2 provision.

Classify the actual program

Marketing names such as medication management, recovery clinic, opioid treatment, maintenance, stabilization, or integrated care provide context without settling the definition. Review the services furnished, program structure, federal assistance, professional and facility authority, and treatment purpose.

Keep clinical and payer decisions separate

The HHS Part 2 fact sheet addresses privacy alignment. Qualified clinicians decide individual treatment. Regulators, payers, contracts, licenses, accreditation, and state rules may impose separate requirements for medications, settings, staffing, enrollment, authorization, claims, and records.

Verify the defined service facts

Document the long-term pharmacotherapy, SUD context, purpose related to pathological pursuit of reward or relief, support for remission of symptoms, responsible clinical roles, program, site, service model, effective dates, and source records. Preserve which Part 2 workflow relies on the classification.

Do not decide from a billing code, program name, medication alone, directory label, or payer category. Review actual function and clinical governance.

Distinguish related program terms

Separate maintenance treatment from withdrawal management, short-term stabilization, induction, tapering, general medication management, emergency care, and nonpharmacologic services. A program may perform more than one function, and its role can vary by service or site. Record the boundary rather than assigning one label to the entire organization.

Update directories and routing when services change. Avoid assuming every SUD pharmacotherapy is maintenance treatment.

Keep clinical care with qualified professionals

Qualified clinicians determine diagnosis, medication, dose, monitoring, contraindications, interactions, adherence, remission, safety, and changes under professional standards and applicable law. The definition does not provide a protocol or patient advice. Escalate urgent symptoms and medication concerns through clinical procedures.

Programs separately verify facility, professional, pharmacy, controlled-substance, payer, consent, staffing, record, and emergency requirements.

Apply the classification to privacy decisions

Some Part 2 provisions use maintenance-treatment program status as a recipient or pathway boundary. Verify the actual site and function, patient, event, consent, data, purpose, distance or other condition where applicable, recipient authentication, and secure route. The classification is one gate among several.

Preserve the source and effective dates. Reassess new medications, protocols, sites, licenses, ownership, program closures, or service redesign.

Audit records and representations

Compare policies, clinical workflows, medication records, directories, referrals, payer descriptions, marketing, coding, interfaces, disclosures, and patient communication. Review both services included and excluded under the definition. Investigate labels that do not match operations.

Correct misrouting, stale directories, unsupported program status, documentation gaps, and disclosures based only on names. The HHS fact sheet describes privacy alignment, not treatment standards.

Preserve the classification decision

Maintain an effective-dated service record showing the program and site, clinical model, pharmacotherapies, long-term purpose, SUD-remission relationship, clinical and operational owners, licenses, directory entries, related privacy pathways, and supporting sources. Link changes in protocols, medications, staffing, location, ownership, or payer description to a review before routing and consent systems are updated.

Use patient-facing language that explains the service without guaranteeing a medication or duration. Keep program classification out of general administrative displays when it would reveal unnecessary SUD information. When two teams disagree about the label, preserve the facts and escalate rather than allowing billing, marketing, or software configuration to decide clinical and regulatory meaning.

Example

Fourteen service lines are classified. Eleven preserve pharmacotherapy, long-term purpose, SUD population, program facts, clinical owner, authority, Part 2 route, and evidence; three rely on a product name. Completeness is 11 of 14 service lines.

Maintenance-treatment checklist

• verify long-term pharmacotherapy, SUD context, remission support, and service purpose;
• distinguish withdrawal, stabilization, taper, emergency, and other medication functions;
• keep patient-specific diagnosis and medication decisions with qualified clinicians;
• apply separate facility, professional, pharmacy, payer, safety, and consent rules;
• use program status as one gate within the actual Part 2 pathway; and
• audit workflows, records, directories, coding, marketing, routing, and changes.

Maintenance treatment is a functional definition grounded in long-term pharmacotherapy and remission support. Program labels alone cannot establish it.